U.S. Marketed Products
This information is intended for U.S. healthcare professionals only.
In the United States, we have the following marketed product:
- ANGIOMAX® (bivalirudin) for Injection in cardiovascular care.
Please see the full prescribing information and Important Safety Information for this product below.
Angiomax® (bivalirudin) for Injection
On January 5, 2018, we divested the following products to Melinta Therapeutics, Inc., as part of the sale of our infectious disease business unit to Melinta. As a result, we no longer market these products:
- VABOMERE™ (meropenem and vaborbactam) for injection in infectious disease care
- ORBACTIV® (oritavancin) for injection in infectious disease care
- MINOCIN® (minocycline) for injection in infectious disease care
Please see www.melinta.com/products for full prescribing information and Important Safety Information for these products.
Global Medical Information
The Global Health Science Center (GHSC) Medical Professionals are available to answer your medical information requests, or receive adverse event reports, other safety related information, and product complaints.
Please click below to contact the Global Health Science Center.
Alternatively, adverse events may be reported to the FDA MedWatch Reporting System by phone at 1 800 FDA 1088 (1 800 332 1088) or by mail using Form FDA 3500 at www.fda.gov/medwatch